Deutsche Bank AG Purchases Shares of 320,037 Natera, Inc. $NTRA

Key Points

• Deutsche Bank acquired 320,037 Natera shares in the second quarter, valued at approximately $86.9 million and representing about 0.22% of the company. Institutional investors collectively own 99.90% of Natera.
• Analysts maintain a positive outlook, with Natera receiving a “Moderate Buy” consensus rating and an average price target of $319.38. Recent targets range as high as $375.
• Natera reported quarterly revenue of $752.75 million, up 37.7% year over year, and posted an adjusted loss of $0.47 per share—slightly better than analysts’ expectations.

Deutsche Bank AG purchased a new stake in shares of Natera, Inc. (NASDAQ:NTRA - Free Report) in the 2nd quarter, according to the company in its most recent disclosure with the SEC. The institutional investor purchased 320,037 shares of the medical research company's stock, valued at approximately $86,874,000. Deutsche Bank AG owned about 0.22% of Natera as of its most recent SEC filing.

Several other institutional investors have also recently made changes to their positions in NTRA. Horizon Investments LLC lifted its holdings in Natera by 22.0% during the fourth quarter. Horizon Investments LLC now owns 244 shares of the medical research company's stock valued at $56,000 after purchasing an additional 44 shares in the last quarter. Parallel Advisors LLC increased its stake in shares of Natera by 5.5% in the first quarter. Parallel Advisors LLC now owns 905 shares of the medical research company's stock worth $181,000 after purchasing an additional 47 shares in the last quarter. First Horizon Corp raised its position in shares of Natera by 5.5% during the 1st quarter. First Horizon Corp now owns 982 shares of the medical research company's stock valued at $196,000 after purchasing an additional 51 shares during the period. Siemens Fonds Invest GmbH raised its position in shares of Natera by 3.1% during the 3rd quarter. Siemens Fonds Invest GmbH now owns 1,804 shares of the medical research company's stock valued at $290,000 after purchasing an additional 54 shares during the period. Finally, Alamea Verwaltungs GmbH lifted its stake in shares of Natera by 2.9% during the 4th quarter. Alamea Verwaltungs GmbH now owns 2,229 shares of the medical research company's stock valued at $515,000 after buying an additional 62 shares in the last quarter. Institutional investors own 99.90% of the company's stock.

Analyst Ratings Changes

Several equities analysts have recently commented on NTRA shares. The Goldman Sachs Group began coverage on shares of Natera in a report on Friday, June 5th. They issued a "neutral" rating and a $245.00 target price on the stock. TD Cowen lifted their price target on shares of Natera from $325.00 to $340.00 and gave the company a "buy" rating in a report on Friday, August 7th. BTIG Research boosted their price target on shares of Natera from $290.00 to $320.00 and gave the stock a "buy" rating in a research note on Friday, August 7th. Robert W. Baird set a $348.00 price target on shares of Natera in a research note on Friday, August 7th. Finally, Canaccord Genuity Group set a $375.00 price objective on shares of Natera in a report on Friday, August 7th. Two analysts have rated the stock with a Strong Buy rating, fifteen have given a Buy rating, four have assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, Natera has an average rating of "Moderate Buy" and an average target price of $319.38.

Natera Stock Performance

NTRA stock opened at $324.84 on Friday. The firm has a fifty day moving average price of $271.84 and a 200 day moving average price of $228.67. Natera, Inc. has a fifty-two week low of $157.43 and a fifty-two week high of $333.56. The firm has a market cap of $46.82 billion, a PE ratio of -238.85 and a beta of 1.51.

Natera (NASDAQ:NTRA - Get Free Report) last released its quarterly earnings results on Thursday, August 6th. The medical research company reported ($0.47) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.49) by $0.02. Natera had a negative net margin of 7.11% and a negative return on equity of 11.38%. The company had revenue of $752.75 million for the quarter, compared to the consensus estimate of $661.24 million. During the same quarter in the prior year, the firm earned ($0.74) earnings per share. Natera's revenue was up 37.7% on a year-over-year basis. On average, equities analysts predict that Natera, Inc. will post -1.02 EPS for the current year.

Insider Buying and Selling at Natera

In other news, insider John Fesko sold 295 shares of the company's stock in a transaction dated Monday, August 3rd. The shares were sold at an average price of $267.99, for a total transaction of $79,057.05. Following the sale, the insider directly owned 183,774 shares in the company, valued at approximately $49,249,594.26. This represents a 0.16% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Solomon Moshkevich sold 3,410 shares of the stock in a transaction dated Monday, August 3rd. The shares were sold at an average price of $265.58, for a total transaction of $905,627.80. Following the completion of the transaction, the insider directly owned 129,019 shares of the company's stock, valued at approximately $34,264,866.02. The trade was a 2.57% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last 90 days, insiders have sold 181,045 shares of company stock valued at $41,330,968. Corporate insiders own 5.05% of the company's stock.

About Natera

Natera is a global diagnostics company that develops and commercializes cell-free DNA and other genetic testing technologies for clinical applications. The company focuses on three principal areas: reproductive health (including non-invasive prenatal testing and carrier screening), oncology (tumor-informed assays for minimal residual disease and recurrence monitoring), and organ transplantation (cell-free DNA tests to detect allograft injury). Natera combines laboratory testing, proprietary bioinformatics, and clinical reporting to deliver personalized genetic information to clinicians and patients.

Key product offerings include Panorama, a non-invasive prenatal test that screens for fetal chromosomal abnormalities and select single-gene conditions; Horizon carrier screening for inherited conditions; Signatera, a personalized, tumor-informed assay used for detecting minimal residual disease and monitoring treatment response in cancer patients; and Prospera, a donor-derived cell-free DNA test used to assess the risk of organ rejection.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source